Jesus San Miguel's guest appearances

Jesus San Miguel

EHA Hematology Podcast

HealthTree Podcast for Multiple Myeloma

14th International Myeloma Workshop (IMW) 2013

18th European Haematology Association (EHA) Congress

Antonio Palumbo

Sergio Giralt

Pieter Sonneveld

David Siegel

Mike Thompson

Beth Israel

Damian Green

Sarah Cannon

Keith Stewart

Mark Newman

Paul Richardson

Stephen Harding

Kenneth Anderson

Vincent Rajkumar

Thomas Martin

OwlTail

Join us as we talk with renown myeloma expert Dr. Jesus San Miguel of the University Hospital of Salamanca about high risk myeloma, recent findings of the International Myeloma Working Group and his work on minimal residual disease.

mPatient Myeloma Radio: Dr. Jesus San Miguel, MD, PhD, University of Navarra

Prof Jesus San Miguel talks with ecancer at the 18th EHA Congress about the MM-003 trial.MM-003 is a large, multi-centre phase III study that assessed the efficacy and safety of a new drug, pomalidomide (POM) in combination with low-dose dexamethasone (POM LoDex) and compared this combination with high dose dexamethasone in MM patients with late stage disease which have previously failed lenalidomide and bortezomib.

Prof Jesus San Miguel talks with ecancer at the 18th EHA Congress about the MM-003 trial. MM-003 is a large, multi-centre phase III study that assessed the efficacy and safety of a new drug, pomalidomide (POM) in combination with low-dose dexamethasone (POM LoDex) and compared this combination with high dose dexamethasone in MM patients with late stage disease which have previously failed lenalidomide and bortezomib.

Pomalidomide prolongs survival in refractory multiple myeloma patients: Dr Jesus San Miguel

The use of novel agents bortezomib, lenalidomide and thalidomide in Asian patients is discussed. Bortezomib is used as induction therapy and lenalidomide and thalidomide are reserved for relapsed or refractory patients in Japan. Rare reports of complications with these agents have been reported, However these are not believed to be treatment related.The increased incidence of cancer in survivors of the atomic bomb during World War II has been addressed at IMW.Results from the Life Span Study investigating radiation effects on leukaemia, lymphoma and MM incidence in atomic bomb survivors were presented at this year's IMW meeting. This study found that the radiation exposure associated with this may be a possible predisposing factor for MGUS. However, the incidence of multiple myeloma appears to be the same as Western populations.Overall, the incidence of MM appears to be lower in the Asian population, but higher rates have been noted in Vietnamese patients.A number of clinical studies are ongoing covering the use of novel therapies, autologous stem cell transplant and maintenance therapy.

The use of novel agents bortezomib, lenalidomide and thalidomide in Asian patients is discussed. Bortezomib is used as induction therapy and lenalidomide and thalidomide are reserved for relapsed or refractory patients in Japan. Rare reports of complications with these agents have been reported, However these are not believed to be treatment related. The increased incidence of cancer in survivors of the atomic bomb during World War II has been addressed at IMW. Results from the Life Span Study investigating radiation effects on leukaemia, lymphoma and MM incidence in atomic bomb survivors were presented at this year's IMW meeting. This study found that the radiation exposure associated with this may be a possible predisposing factor for MGUS. However, the incidence of multiple myeloma appears to be the same as Western populations. Overall, the incidence of MM appears to be lower in the Asian population, but higher rates have been noted in Vietnamese patients. A number of clinical studies are ongoing covering the use of novel therapies, autologous stem cell transplant and maintenance therapy.

Myeloma in Asia: Prof Miles Prince, Prof Kazuyuki Shimizu, Prof Jesus San Miguel